Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/11/2026

1. ORCL
2. ADBE
3. RH
4. SPY
5. CPRT
6. SEDG
7. TLT
8. PMTS
9. QQQ
10. TENB

Go back to Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
(NASDAQ: PTGX) Delayed: 148.58 +3.42 (2.36%)
Previous Close $145.16    52 Week High $24.52 
Open $147.18    52 Week Low $10.02 
Day High $150.48    P/E N/A 
Day Low $146.69    EPS $0.00 
Volume 12,830